Global Preclinical In-vivo Imaging System Market Size By Type (Optical Imaging System, Nuclear Imaging System), By Application (Hospitals, Veterinary Clinics), By Region, And Segment Forecasts, 2023 t...

The Global Preclinical In-vivo Imaging System Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 2.4 billion by 2031, growing at a CAGR of 10.2% during the forecast period of 2023–2031. The market is primarily driven by the increasing demand for non-invasive imaging techniques in drug development, the rising prevalence of chronic diseases, and the surge in biomedical research activities. Preclinical in-vivo imaging systems are widely used in research laboratories and pharmaceutical companies for visualizing biological processes in animal models in real-time, facilitating efficient and targeted drug discovery and validation.

Drivers:

1. Rising Demand for Non-Invasive Imaging in Drug Development:

The need for efficient and non-destructive methods to study disease progression, pharmacokinetics, and therapeutic responses is fueling the adoption of preclinical in-vivo imaging systems. These technologies reduce animal usage and provide real-time insights, accelerating the drug discovery pipeline.

2. Growth in Biomedical and Cancer Research:

A surge in funding and interest in cancer and neurological disease research is significantly boosting the use of imaging modalities such as PET, MRI, and bioluminescence imaging. These tools are essential for tracking disease development and therapeutic responses.

3. Technological Advancements in Imaging Modalities:

Innovations in imaging platforms—such as multimodal systems combining optical, nuclear, and magnetic imaging—are enhancing resolution, accuracy, and speed. These improvements are increasing adoption across research institutions globally.

Restraints:

1. High Capital and Maintenance Costs:

The initial investment required for sophisticated imaging systems, along with ongoing operational costs, can be prohibitively high, particularly for small laboratories and academic institutions.

2. Ethical Concerns and Regulatory Constraints:

Despite their non-invasive nature, in-vivo imaging systems rely on animal models, which raise ethical concerns and require strict regulatory compliance, potentially hampering market expansion.

Opportunity:

1. Expansion of CRO Services and Academic Collaborations:

The growing trend of outsourcing preclinical research to contract research organizations (CROs) and the increase in public-private partnerships in academic settings offer significant market expansion opportunities.

2. Rising Demand in Emerging Economies:

Emerging countries in Asia-Pacific and Latin America are investing in R&D infrastructure, which presents untapped opportunities for preclinical imaging system providers as these regions modernize their pharmaceutical and research ecosystems.

Market by System Type Insights:

Based on system type, Optical Imaging Systems held the largest market share in 2023 due to their affordability, sensitivity, and non-invasive capabilities. These systems are preferred in oncology, neurology, and infectious disease research. However, Multimodal Imaging Systems are expected to witness the fastest growth due to their comprehensive capabilities and ability to provide both structural and functional data from a single study.

Market by End-use Insights:

In terms of end-use, Pharmaceutical & Biotechnology Companies dominated the market in 2023, accounting for over 50% of the market share. These entities rely heavily on in-vivo imaging systems for preclinical drug testing and development. The Academic & Research Institutes segment is anticipated to grow steadily, driven by increasing government and institutional funding for biomedical research.

Market by Regional Insights:

North America led the global market in 2023, supported by a well-established pharmaceutical industry, robust research infrastructure, and high R&D spending. However, Asia-Pacific is projected to be the fastest-growing region during the forecast period, driven by expanding biotech sectors, increased funding for life sciences, and rapid infrastructure development in countries like China and India.

Competitive Scenario:

Key players in the global preclinical in-vivo imaging system market include PerkinElmer, Inc., Bruker Corporation, Fujifilm Holdings Corporation, Miltenyi Biotec, Mediso Ltd., LI-COR Biosciences, MR Solutions Ltd., and Aspect Imaging Ltd. Companies are emphasizing innovation in imaging modalities, strategic collaborations, and product portfolio expansion.

Key Market Developments:

In 2023, Bruker Corporation unveiled its next-gen micro-CT scanner for small animal imaging with enhanced resolution and AI-powered analysis.

In 2024, PerkinElmer launched a multimodal imaging system integrating PET and optical imaging for high-throughput preclinical research.

In 2025, Mediso Ltd. expanded its presence in Asia by opening a new R&D facility in Singapore, targeting regional collaboration in biomedical research.

Scope of Work – Global Preclinical In-vivo Imaging System Market

Report Metric Details

Market Size (2023) USD 1.1 billion

Projected Market Size (2